HCPCS Level II code J9255 denotes a 50 mg injectable dose of methotrexate (brand: accord), identified as not therapeutically equivalent to J9260. This product-level billing code is used when administering methotrexate by injection in outpatient and ambulatory infusion settings and is relevant to oncology, rheumatology, and certain autoimmune disease management. Nationally, biologic and chemotherapeutic drug coding matters for accurate clinical documentation, inventory control, and payer reimbursement consistency.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and common sites of service for J9255, along with payer coverage considerations and typical billing practice features. The publication outlines benchmarks and policy updates where available, clarifies the clinical role of methotrexate injections relative to other injectable formulations, and highlights coding distinctions tied to therapeutic equivalence language in the descriptor.

This summary equips billing managers, coding professionals, and revenue leaders with the essential information needed to recognize when J9255 applies, what settings it is commonly billed in, and which national payers are typically involved. Data not available in the input is noted where applicable.